Medtronic plc (MDT) FY2027 Q1 P&L / Income Statement

Medtronic plc (MDT) FY2027 Q1 P&L / Income Statement

Income statement for 2026-04-25 through 2026-07-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

9,756,000,000 US dollars

Cost of products sold, excluding amortization of intangible assets

3,416,000,000 US dollars

Gross profit (calculated)

6,340,000,000 US dollars

Operating costs, including other operating expenses (calculated)

4,576,000,000 US dollars

Operating profit

1,764,000,000 US dollars

Other income (expense), net (calculated)

5,000,000 US dollars

Income before income taxes

1,769,000,000 US dollars

Income tax provision

289,000,000 US dollars

Net income

1,479,000,000 US dollars

Cardiovascular

3,927,000,000 US dollars

Neuroscience

2,678,000,000 US dollars

Medical Surgical

2,279,000,000 US dollars

Diabetes

843,000,000 US dollars

Other operating segment, misc

29,000,000 US dollars

Research and development expense

771,000,000 US dollars

Selling, general, and administrative expense

3,198,000,000 US dollars

Amortization of intangible assets

412,000,000 US dollars

Restructuring charges, net

72,000,000 US dollars

Certain litigation charges, net

0 US dollars

Other operating expense (income), net

123,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Medtronic plc: $1.47 B; to noncontrolling interests: $9.00 M.

• The amounts that make up net income come to $1,480.00 M and net income is $1,479.00 M; the $1.00 M difference is within the rounding of the filed amounts.